Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 8.04 B

Share Price

USD 159.40

Avg Daily Volume

1,537,950

Change (1 day)

-2.60%

Change (1 year)

-24.41%

Change (YTD)

-13.65%

Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 29, 2025: 13.57%

Charles River Laboratories International, Inc. EBITDA Margin is 13.57% for the Trailing 12 Months (TTM) ending March 29, 2025, a -44.69% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 30, 2024 was 24.54%, a -6.25% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending April 01, 2023 was 26.18%, a 9.23% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 26, 2022 was 23.96%, a -6.89% change year over year.
Charles River Laboratories International, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 27, 2021 was 25.74%, a 19.83% change year over year.